2021
“3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer
An O, Song Y, Ke X, So J, Sundar R, Yang H, Rha S, Lee M, Tay S, Ong X, Tan A, Ng M, Tantoso E, Chen L, Tan P, Yong W, Consortium S. “3G” Trial: An RNA Editing Signature to Guide Gastric Cancer ChemotherapyRNA Editing Signature in Gastric Cancer. Cancer Research 2021, 81: 2788-2798. PMID: 33558338, DOI: 10.1158/0008-5472.can-20-2872.Peer-Reviewed Original ResearchConceptsAdvanced gastric cancerRNA editingRNA editing signaturesEditing levelsGastric cancerRNA editing eventsHigher editing levelsAdenosine-to-inosineRNA editing analysisGastric cancer cell linesPredictive biomarkersStratify patientsLevels of editingGene expression profilesPredicting response to chemotherapyEditing sitesEditing eventsMolecular subtypes of gastric cancerCancer cell linesPlatinum-based chemotherapyMetastatic gastric cancerSubtypes of gastric cancerCancer Genome AtlasFirst-line therapyResponse to chemotherapy
2011
Molecular Classification of Gastric Cancer: A New Paradigm
Shah M, Khanin R, Tang L, Janjigian Y, Klimstra D, Gerdes H, Kelsen D. Molecular Classification of Gastric Cancer: A New Paradigm. Clinical Cancer Research 2011, 17: 2693-2701. PMID: 21430069, PMCID: PMC3100216, DOI: 10.1158/1078-0432.ccr-10-2203.Peer-Reviewed Original ResearchConceptsGastric cancer subtypesGastric cancerCancer subtypesClassification of gastric cancerLocalized gastric adenocarcinomaPreoperative clinical trialLocalized gastric cancerSubtypes of gastric cancerDistal gastric cancerExpression analysisCDNA expression analysisIdentified several pathwaysTargeted biopsyPrimary tumorEndoscopic biopsyGastric adenocarcinomaHistological distinctionUnique epidemiologyClinical trialsBioconductor R packageAdequate RNAGene set analysisAnatomical criteriaGene expression dataMolecular drivers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply